Agenus Immunotherapy Acts on Colorectal Cancer on the Rise in Under-50s

 BOT/BAL Combination Shows Promising Results in the Most Prevalent Form of Colorectal Cancer, Affecting 95% of Diagnosed Patients

A randomized Phase 2 study to confirm the comparative safety and efficacy of the BOT and BAL combination has completed enrollment and will be included in an upcoming discussion with the U.S. Food and Drug Administration at a scheduled End-of-Phase 2 Meeting in July. A Phase 3 trial is planned to initiate later this year.

Access the Full Publication:

The full details of this study can be found here.

https://www.biospace.com/article/releases/nature-medicine-reports-agenus-novel-immunotherapy-demonstrates-clinical-activity-against-a-deadly-form-of-colorectal-cancer-on-the-rise-in-americans-under-50/